News & Events about Mirati Therapeutics Inc.
Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX Get Rating) have earned an average recommendation of Hold from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ...
Mirati Therapeutics (NASDAQ:MRTX Get Rating) had its price target cut by Barclays from $169.00 to $90.00 in a research report released on Wednesday, The Fly reports. Several other research firms also recently weighed in on MRTX. B. Riley began coverage on Mirati Therapeutics in a report on ...
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study PR Newswire SAN DIEGO, Dec. 2, 2022 Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer...
Mirati Therapeutics, Inc. (NASDAQ:MRTX Get Rating) insider Charles M. Baum sold 69,256 shares of the companys stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $100.00, for a total transaction of $6,925,600.00. Following the completion of the ...
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO PR Newswire SAN DIEGO, Nov. 28, 2022 SAN DIEGO, Nov. 28, 2022...